Epitope Analysis of Anti-Myeloperoxidase Antibodies in Patients with ANCA-Associated Vasculitis

Shen-Ju Gou, Peng-Cheng Xu, Min Chen*, Ming-Hui Zhao

Renal Division, Department of Medicine, Peking University First Hospital, Peking University Institute of Nephrology, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China

Abstract

Objective: Increasing evidences have suggested the pathogenic role of anti-neutrophil cytoplasmic antibodies (ANCA) directing myeloperoxidase (MPO) in ANCA-associated vasculitis (AAV). The current study aimed to analyze the association between the linear epitopes of MPO-ANCA and clinicopathological features of patients with AAV.

Methods: Six recombinant linear fragments, covering the whole length amino acid sequence of a single chain of MPO, were produced from E.coli. Sera from 77 patients with AAV were collected at presentation. 13 out of the 77 patients had coexistence of serum anti-GBM antibodies. Ten patients also had sequential sera during follow up. The epitope specificities were detected by enzyme-linked immunosorbent assay using the recombinant fragments as solid phase ligands.

Results: Sera from 45 of the 77 (58.4%) patients with AAV showed a positive reaction to one or more linear fragments of the MPO chain. The Birmingham Vasculitis Activity Scores and the sera creatinine were significantly higher in patients with positive binding to the light chain fragment than that in patients without the binding. The epitopes recognized by MPO-ANCA from patients with co-existence of serum anti-GBM antibodies were mainly located in the N-terminus of the heavy chain. In 5 out of the 6 patients, whose sera in relapse recognize linear fragments, the reactivity to linear fragments in relapse was similar to that of initial onset.

Conclusion: The epitope specificities of MPO-ANCA were associated with disease activity and some clinicopathological features in patients with ANCA-associated vasculitis.

Introduction

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) comprises granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and Churg-Strauss syndrome (CSS). ANCA are serological hallmarks for the above-mentioned small vessel vasculitis. Proteinase 3 (PR3) and myeloperoxidase (MPO) are two major target antigens of ANCA in AAV [1]. MPO is the most common target antigen of ANCA in Chinese patients with AAV [2–4]. Even in patients with a clinical picture of GPA, about 60% of them have ANCA directed to MPO [5], [6]. In addition, in about 4–14% of AAV patients, most often MPO-ANCA positive patients, have both serum ANCA and anti-glomerular basement membrane (GBM) antibodies [7], [8].

The pathogenic role of ANCA, especially MPO-ANCA, in AAV was confirmed by animal studies, in vitro studies and clinical observations [9–11]. It has been suggested by several studies that immunological characteristics of MPO-ANCA, including IgG subclasses, epitope specificity, the avidity and titre, were associated with the development of AAV [12–16]. Therefore, we speculated that the differences of the immunological characteristics of MPO-ANCA might contribute to the clinical and pathological heterogeneity.

In AAV, the level of MPO-ANCA was not always consistent with the disease activity [17]. Our previous study found that despite complete remission had been achieved; the avidity and titre of MPO-ANCA did not decrease significantly during remission, as compared to the active stage [18]. Therefore, it is reasonable to speculate that such inconsistency between ANCA levels and disease activity might be attributed to differences in epitope specificity of MPO-ANCA.

Our previous study has preliminarily suggested that the different conformational epitope recognition of MPO-ANCA might contribute to the different disease phenotypes (GPA or MPA) [19]. However, the difference in fine epitopes of MPO-ANCA from patients with different phenotypes needs further investigation. In addition, epitope mapping of MPO, especially linear epitopes, might also provide clues to the pathogenesis of MPO-ANCA-associated vasculitis.
In the present study, we produced six linear recombinant deletion mutants of MPO molecule and analyzed linear MPO epitopes using sera from AAV patients with and without co-existence of serum anti-GBM antibodies. The epitopes recognized by sequential sera of patients with AAV, who suffered at least one relapse, were also studied. The associations between the epitope specificities and clinico-pathological features of the patients were further analyzed.

Materials and Methods

Patients and Sera

Seventy-seven patients with AAV, diagnosed at Peking University First Hospital were recruited. All the patients met the criteria of the Chapel Hill Consensus Conference definition of AAV [20]. At the time of diagnosis, all the patients were positive for perinuclear ANCA (P-ANCA) and MPO-ANCA, and 13 out of the 77 patients had co-existence of serum anti-GBM antibodies. Among the 64 patients without serum anti-GBM antibodies, 21 were classified as GPA and the other 43 were classified as MPA. The diagnosis of GPA was established if both the following criteria were met: (i) Chapel Hill Consensus Conference (CHCC) definition [20]. Patients with systemic vasculitis and the presence of granulomatous inflammation in a biopsy specimen of the respiratory tract or the presence of clinical signs strongly suggestive of granulomatous disease in the respiratory tract, which comprised involvement of the upper respiratory tract with nasal inflammation (purulent/bloody nasal discharge), sinusitis or otitis media or lower respiratory tract manifestation with pulmonary nodules, cavities or fixed infiltrate. (ii) American College of Rheumatology (ACR) classification criteria of GPA [21]. The diagnosis of MPA was based on the CHCC definition [20]. Patients were classified as MPA if they had systemic vasculitis, and the absence of granuloma formation in a biopsy specimen and the absence of clinical signs compatible with GPA, which is strongly suggestive of granulomatous disease.

The serum samples were collected at the time of diagnosis and before commencement of immunosuppressive therapy. Patients with secondary vasculitis were excluded. Among the 64 patients without anti-GBM antibodies, ten patients showed sustained positivity in serum MPO-ANCA and experienced at least one relapse event during follow up. For each of these ten patients, three serum samples were collected respectively: (i) active phase of initial onset before commence of immunosuppressive therapy; (ii) remission after immunosuppressive therapy; and (iii) active phase of relapse. The serum samples from all subjects were obtained and kept at −70°C until use. The research was in compliance of the Declaration of Helsinki and approved by the ethics committee of the Peking University First Hospital. Written informed consent was obtained from each participant.

Detection of MPO-ANCA and Anti-GBM Antibodies

ANCA assays were performed by indirect immunofluorescence (EUROIMMUN, Lübeck, Germany) using ethanol-fixed human neutrophils. Antigen-specific enzyme-linked immunosorbent assay (ELISA) was performed against purified myeloperoxidase (MPO) [23]. The sensitivity and specificity of the MPO-ANCA ELISA assay were 50% and 97%, respectively. Anti-GBM assays were performed by ELISA using purified bovine χ3(IV)NC1 as solid phase antigen, with confirmation of antibody specificity by ELISA against recombinant human χ3(IV)NC1 [24].

Preparation of Recombinant MPO Fragments

Six linear fragments of myeloperoxidase (MPO), i.e., P, L, H1, H2, H3 and H4 were prepared as deletion mutants of MPO from E.coli. The amino acid sequences of the six fragments were as follows: 49–164 for propeptide (P); 165–272 for light chain (L); 279–409 for the N terminal of the heavy chain (H1), 399–519 for the second part of the heavy chain (H2); similarly, 510–631 for H3 and 622–745 for H4 (Figure 1). The cDNA of human MPO was a gift from Dr. Thomas Hellmark of Lund University Hospital.

Synthesis of Primer Oligonucleotides

Primer oligonucleotides derived from the cDNA sequences of MPO were synthesized by Invitrogen Company. The sequences of them were as follows. 5’-primers: P, ATGGGGGTTCCTCCTTTTCTTTCTCTCACG; L, CGCAGGGGCAACCATATGGAAGCTTGGCCGAGGCA; H1, GGAGAATTTCATATGTTCAACTGCGAGAC; H2, GGAGAATTTCATATGTTCAACTGCGAGAC; H3, GGAGAATTTCATATGTTCAACTGCGAGAC; H4, GGAGAATTTCATATGTTCAACTGCGAGAC.

Figure 1. Schema of linear epitopes of MPO-ANCA. Six recombinant linear fragments, named P, L, H1, H2, H3 and H4, were produced using E.coli. P represents propeptide part, amino acids (aa) 49–164; L represents light chain, aa165–272; H1–H4 represent four fragments of the heavy chain, H1 for aa279–409, H2 for aa399–519, H3 for aa510–631 and H4 for 622–745. There were about 10 amino acids overlapping between the two adjacent fragments on the heavy chain. doi:10.1371/journal.pone.0060530.g001
Amplification of DNA Fragments by Polymerase Chain Reaction (PCR)

MPO cDNA encoding each fragment was amplified by PCR. The reaction mixture (50 μl) contained 50 ng of the cDNA clone as a template, 1 μl of the upstream primer (10 μM), 1 μl of the downstream primer (10 μM), 25 μl of 2×Lamp MasterMix. The amplification was performed in a DNA thermal cycler by programmed incubation for 30 sec at 94°C, for 30 sec at 55°C, and for 30 sec at 72°C and repeated 30 times.

Construction of MPO Fragments Genes

The PCR products of different MPO fragments were digested with enzymes and inserted into the plasmid vectors. L chain (L) were digested with enzymes NdeI and NotI and inserted into the expression vector pET28a (Merck, Germany). H1 and H3 were inserted into Hind III and PshAI sites of plasmid pET-42a (+) (Novagen, USA). H1 and H3 was inserted into NdeI and XhoI sites of plasmid pET-30a (+) (Novagen, USA).

Confirmation of the Base Sequences of the Fragments

After the ligation of plasmid vectors and the target fragments, the newly formed plasmids were transformed into competent bacteria DH5α (CwBio, Beijing, China). Positive bacteria were selected by selective culture-medium and the positive plasmid was sequenced by SinoGenoMax Company (Beijing, China). The base sequence of the target fragments were confirmed by DNAMAN.
software. The correctly constructed plasmid were selected and transformed into competent bacteria BL21 (Cwbio, Beijing, China) for expression.

Expression of Recombinant P, L, H1, H2, H3 and H4 Constructs in Vectors

E. coli expressing each fragment of MPO was inoculated into 10 mL of Luria-Bertani medium (tryptone 10 g/L, yeast extract 5 g/L, NaCl 10 g/L) supplemented with kanamycin (100 μg/ml) in a shaker flask. The cells were grown with shaking (250 rpm) overnight at 37°C. The bacterial suspension was diluted to 1/100 with fresh medium and further incubated at 37°C with shaking at 250 rpm. When the absorbance at 600 nm became approximately 0.6–0.8, IPTG (0.4 mM) was added, and the mixture was incubated for a further 4 hr. The cells were harvested by centrifugation at 8000 rpm for 2 min.

Purification of Insoluble Proteins with 6x His-tagged Protein Purification Kit

The harvested bacterial cells were lysed by ultrasonic and the precipitant was collected. The inclusion bodies in the precipitant were suspended in buffer 1 consisting of 50 mM Tris, 1 mM EDTA and 0.5% Triton (pH7.9). After centrifugation at 10000 rpm for 20 min at 4°C, newly formed precipitant was collected and resuspended in buffer 2 consisting of 50 mM Tris, 1 mM EDTA and 1.0%Triton (pH7.9). Similarly, buffer 3 (50 mM Tris, 1 mM EDTA and 1 M urea, pH7.9), buffer 4 (50 mM Tris, 1 mM EDTA, 2 M urea, pH7.9) and buffer 5 (50 mM Tris, 1 mM EDTA, 4 M urea, pH7.9) were sequentially used to wash the insoluble target proteins in inclusion bodies. Then, the inclusion bodies were dissolved in 8 M urea buffer (50 mM Tris, 8 M urea, pH7.9) and the supernatant was collected by centrifugation at 10000 rpm for 20 min at 4°C. Finally, the target protein fragments were purified by 6x His-tagged protein purification kit (Cwbio, Beijing, China).

Determination of the Purity of Recombinant Peptides

The recombinant proteins were treated with a sampling buffer (SDS 3 g, bromophenol blue 0.01 g, glycerol 2 ml, and 2-mecaptoethanol 1 ml, deionized water 15 ml) for 3 min at 100°C. Then the recombinant proteins were applied to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The gel was stained with MemGel staining solution (Applygen, Beijing, China).

Determination of the Reactivity of Recombinant Proteins of MPO by ELISA

Highly purified recombinant MPO proteins were reconstituted to 10 μg/ml with coating buffer (0.05 M bicarbonate buffer, pH 9.6). A 100 μl portion of the mixture was then plated to a well of a polystyrene microtitre plate (Nunc Immunoplate; Nunc, Roskilde, Denmark) and kept overnight at 4°C. Every plate contained native MPO (2 μg/well) as a positive antigen control. The plate was washed three times with PBS containing 0.1% Tween-20 (PBST) (Chemical Reagents, Beijing, China). 2% BSA diluted by PBS was used to block the non-specific binding sites. The sera of subjects were diluted to 1:100 by PBST/0.5 M NaCl (NaCl 0.5 M, KCl 2.7 mM, Na2HPO4 10 mM, KH2PO4 2 mM, pH 7.4) and were added in duplication. Every plate contained positive, negative and blank controls. The plate was incubated at 37°C for 1 hr and then washed three times with PBST, and the binding was detected with alkaline phosphatase-conjugated goat anti-human IgG (Fc specific; Sigma, St Louis, MO, USA) at a dilution of 1:5000. The plate was washed three times with washing buffer and the P-nitrophenyl phosphate (pNPP, 1 mg/ml; Sigma) was used in substrate buffer [1 M diethanolamine and 0.5 mM MgCl2 (pH 9.8)]. The results were recorded as the net absorbance value (the absorbance values of peptide-coated wells minus the absorbance values of antigen-free wells) at 405 nm (A 405 nm) and samples were considered positive if the A 405 nm exceeded mean+2 S.D. (cutoff value) of the A 405 nm of the sera from 35 normal blood donors.
Inhibition ELISA

Cross-reaction between antibodies against the recombinant proteins and native myeloperoxidase was investigated using inhibition ELISA. In brief, polystyrene microtiter plates were coated with myeloperoxidase. The diluted sera were preincubated with either myeloperoxidase or recombinants (P, L, H1, H2, H3 and H4), at increasing concentrations from 0.5 to 50 μg/ml at 37°C for 2 hr. The mixtures were then transferred to the myeloperoxidase-coated microtiter plates and the bound autoantibodies were detected with alkaline phosphatase-conjugated secondary antibodies, as described above. The absorbance value (OD) of the sera without the inhibitor was defined as 1, and the absorbance value of the sera preincubated with inhibitor was expressed relative to that. Similarly, the cross-reaction between antibodies against the H1 fragment and human α3[IV]NC1 was also performed using inhibition ELISA with a polystyrene microtiter plate coated with human α3[IV]NC1.

Statistical Analysis

Differences in quantitative parameters were assessed using t test (for data that were normally distributed) or nonparametric test (for data that were not normally distributed). Differences in qualitative data were compared using χ² tests. The difference was considered significant if a P value was <0.05. Analysis was performed with SPSS statistical software package (version 13.0, Chicago, IL, USA).

Results

General Data of Patients with AAV

Among the 64 AAV patients without anti-GBM antibodies, 32 were male and 32 were female, with an age of 60.5±15.1 (range 15–83) years at diagnosis. The clinical and histopathological data of the 64 patients were listed in Table 1. The clinical and laboratory data of the 13 AAV patients with co-existing anti-GBM antibodies were listed in Table 2. Among the ten patients with AAV who experienced at least one relapse, the Birmingham
Vasculitis Activity Scores (BVAS) were 19.8±6.6 (range 13–36) at initial onset, zero in remission and 7.7±3.2 (range 3–12) in relapse, respectively.

**Purification of Recombinant Proteins**

All the six recombinant MPO fragments were highly purified as proteins tagged with histidines with over 80% purity by Ni-NTA column chromatography. However, we failed to express the fragments P, H2 and H4 with hexamer histidine-tag. We could only express these three fragments with histidine and glutathione S-transferase (GST) tags simultaneously (Figure 2). No serum bound to GST tags, which was confirmed by both Western blot analysis and ELISA (data not show).

**The Reactivity of ANCA against the Linear Peptides of MPO**

The cutoff values of positive reactivity, built up by normal sera testing, for recombinants P, L, H1, H2, H3 and H4 were 0.14, 0.14, 0.23, 0.20, 0.14 and 0.23, respectively.

The MPO-ANCA positive sera were demonstrated to recognize all the six constructed linear protein fragments. Sera from 45 out of the 77 (58.4%) patients could recognize at least one peptide.

Among the sera from the 64 AAV patients without co-existing anti-GBM antibodies, 37(57.8%) showed a positive reaction to one or more linear fragments of the MPO chain. The reactivity distributed throughout the MPO molecule, although more frequently focused on the N-terminus of the heavy chain. No significant difference in the recognition frequency to different peptides was found between patients with GPA and patients with MPA. However, patients with GPA seemed to recognize the C-terminus of the MPO molecule (H3 and/or H4) more frequently than those with MPA (Figure 3A, 3B; table 1).

Among the 13 AAV patients with co-existence of anti-GBM antibodies, sera of 8(61.5%) patients recognized linear protein fragments of MPO. Interestingly, all these patients reacted with the H1 fragment (Table 2). The reactivity was much more restricted to the H1 fragment, which was highly different from that of AAV patients without anti-GBM antibodies (Figure 3C, 3D; table 1). The recognition frequency to H1 fragment tends to be higher in AAV patients with anti-GBM antibodies than that of AAV patients without anti-GBM antibodies (61.5% vs. 34.4%, $\chi^2=3.352$, $P=0.067$). In addition, six out of the 13 AAV patients with coexisting anti-GBM antibodies recognized one peptide only, while the number of fragments recognized by AAV patients without anti-GBM antibodies varies widely.

Among the 10 AAV patients who experienced relapse after remission, the number of fragments recognized in remission was significantly less than that in initial onset ($2.0\pm0.6$ vs. $5.0\pm2.3$, $P=0.009$, Figure 4). The binding pattern in 5 patients (patient No. 4, 5, 7, 8 and 10 in Table 3) changed obviously during a median follow-up of 30 (range 3–49) months. The binding to the linear peptides turned negative during follow-up in 4 of the 5 patients. The changing of the binding pattern in the other 5 patients was not obvious. In addition, in 5 out of the 6 patients, the number of fragments recognized was significantly less in relapse ($1.2\pm0.7$ vs. $3.3\pm1.5$, $P=0.009$, Figure 5). The binding pattern in 5 patients (patient No. 4, 5, 7, 8 and 10 in Table 3) changed obviously during a median follow-up of 30 (range 3–49) months. The binding to the linear peptides turned negative during follow-up in 4 of the 5 patients. The changing of the binding pattern in the other 5 patients was not obvious. In addition, in 5 out of the 6 patients, the number of fragments recognized was significantly less in relapse ($1.2\pm0.7$ vs. $3.3\pm1.5$, $P=0.009$, Figure 5).

| Patient NO. | Sex | Age (years) | Initial Scr (μmol/L) | Anti-GBM level | MPO-ANCA level | Epitopes recognized |
|-------------|-----|-------------|----------------------|----------------|----------------|---------------------|
| 1           | F   | 41          | 454                  | 134            | 76             | H1                  |
| 2           | M   | 13          | 500                  | 87             | 137            | H1                  |
| 3           | M   | 66          | 1000                 | 116            | 68             | H1                  |
| 4           | M   | 62          | 991                  | 176            | 32             | L/H1/H2/H3          |
| 5           | M   | 66          | 1120                 | 192            | 94             | H1/H3               |
| 6           | M   | 67          | 968                  | 68             | 78             | H1                  |
| 7           | M   | 64          | 291                  | 40             | 83             | –                   |
| 8           | M   | 70          | 1000                 | 43             | 159            | –                   |
| 9           | M   | 59          | 464                  | 24             | 62             | H1                  |
| 10          | F   | 77          | 1003                 | 91             | 40             | H1                  |
| 11          | M   | 67          | 165                  | 64             | 95             | –                   |
| 12          | F   | 45          | 740                  | 83             | 176            | –                   |
| 13          | M   | 58          | 218                  | 85             | 75             | –                   |

Table 2. Clinical and laboratory data of the AAV patients with co-existing anti-GBM antibodies.

$'-$', negative for any fragment test.
doi:10.1371/journal.pone.0060530.t002

Figure 4. The number of protein fragments of MPO recognized in different stages of disease activity of AAV.
doi:10.1371/journal.pone.0060530.g004
whose sera in relapse recognize linear fragments (patient No. 1, 2, 3, 6, 7 and 9 in Table 3), the reactivity to linear fragments in relapse was similar to that of initial onset. In addition, at initial onset of ANCA-associated vasculitis, 5 of 10 patients (patient No. 1, 6, 8, 9 and 10 in Table 3) recognized the H2 fragments. All of these binding to H2 fragments turned negative in remission (Table 3).

Association of the Target Fragments of MPO with Clinicopathological Features of Patients with AAV

Among the 64 AAV patients without anti-GBM antibodies, no significant differences in clinical parameters were found between patients with antibodies binding to the recombinant fragments and those without any binding.

The BVAS and the initial serum creatinine were significantly higher in patients with positive binding to L fragment than that in patients with negative binding (24.0±6.0 vs. 19.2±6.0, P = 0.021; 472.2±310.3 μmol/L vs. 311.5±213.1 μmol/L, P = 0.04, respectively). Patients with positive binding to L fragment had significantly higher proportion of gastrointestinal system involvement than those with negative binding (45.5% vs. 11.3%, χ² = 5.25, P = 0.022). In addition, patients with antibodies to the light chain reacted to higher number of the recombinant fragments than those without [1 (1, 3) vs. 0 (0, 2), P = 0.023]. The BVAS were significantly lower in patients with positive binding to H1 fragment than that in patients with negative binding (17.18±6.54 vs. 21.60±5.55, P = 0.006). In renal histology of 47 patients who received renal biopsy, the percentage of normal glomeruli in the renal specimens was significantly higher in patients with positive binding to H4 than that in patients with negative binding (42.0±30.4% vs. 22.9±23.3%, P = 0.025). The percentage of glomeruli with cellular crescents in the renal specimens was significantly lower in patients with positive binding to H4 than that in patients with negative binding (16.0±14.0% vs. 33.2±27.8%, P = 0.01).

Cross-reaction of Antibodies

To investigate the cross-reaction between antibodies against the recombinant proteins and native myeloperoxidase, inhibition ELISA was performed. Binding of native myeloperoxidase IgG was strongly inhibited by soluble myeloperoxidase and H3 (inhibition rate >30%), but not the recombinant fragments P, L, H1, H2 or H4 (inhibition rate <30%, Figure 5A). This may indicated that antibodies against P, L, H1, H2 and H4 were distinct from that against native myeloperoxidase, while antibodies

![Figure 5. The results of antigen inhibition ELISA.](https://www.plosone.org/)

**Table 3. Clinical, laboratory features and results of the ten patients with AAV who experienced relapse.**

| Patient NO. | Sex | Age (years) | Diagnosis | TI (months) | MPO-ANCA level | Peptides recognized |
|-------------|-----|-------------|-----------|-------------|----------------|-------------------|
| 1           | F   | 63          | MPA       | 13          | 115            | P/L/H1/H2/H4       |
| 2           | M   | 68          | MPA       | 34          | 98             | P/H1/H2/H4         |
| 3           | F   | 65          | MPA       | 19          | 62             | P/H1/H2/H4         |
| 4           | F   | 70          | GPA       | 3           | 105            | H1/H2/H4           |
| 5           | M   | 44          | MPA       | 25          | 158            | H1/H2/H4           |
| 6           | F   | 65          | MPA       | 8           | 20             | H1/H2/H4           |
| 7           | F   | 50          | MPA       | 30          | 184            | H1/H2/H4           |
| 8           | M   | 71          | GPA       | 49          | 88             | H1/H2/H4           |
| 9           | M   | 46          | MPA       | 13          | 143            | H1/H2/H4           |
| 10          | M   | 52          | MPA       | 34          | 92             | H1/H2/H4           |

TI, time interval between the initial onset and the relapse of disease; ‘-‘, negative for any fragment test.

doi:10.1371/journal.pone.0060530.t003

Epitopes of MPO-ANCA
against H3 partially cross-reacted with that against native myeloperoxidase.

Since all the 8 patients with anti-GBM antibodies and anti-fragments antibodies reacted to the H1 fragment, amino acid sequences of α3(IV)NC1 and H1 fragment were compared using DNAMAN software. The integral identity of the two sequences was low (2.6%), but the amino acid sequences 107–112 (GRALEP) of α3(IV)NC1 were quite similar to amino acid sequences 373–378 (GRALLP) of MPO in H1 fragment. In addition, inhibition ELISA was also performed to investigate the antigenic similarity of α3(IV)NC1 and the H1 fragment. Binding of α3(IV)NC1 IgG was strongly inhibited by soluble α3(IV)NC1 but not the H1 fragment (Figure 5B), which indicated that antibodies against α3(IV)NC1 and H1 fragment were two distinct populations.

**Discussion**

MPO-ANCA was confirmed to be pathogenic in ANCA-associated vasculitis by animal studies, in vitro studies and clinical studies [9–11]. Epitope specificity, one of the major immunological characteristics of MPO-ANCA, was speculated to be contribute to the heterogeneity of clinical features in AAV [14], [19]. To date, the epitope specificities, including both conformational and linear epitopes, of MPO-ANCA have not been clearly defined. Limited information is available with regard to whether the epitope specificities are associated with disease activities or clinicopathological features [25–28]. It has been demonstrated that MPO-ANCA mainly recognizes conformational epitopes on MPO molecule. However, linear epitopes of MPO might also provide important information on the pathogenesis of MPO-ANCA. The key amino acid motif or back bone amino acid structure derived from the fine linear epitope of MPO may also be used to identify potential causative microbial agents using molecular mimicry theory. To address these issues, we detected the epitope specificities of MPO-ANCA in sera of AAV patients with different phenotypes and patients at different stages of disease activities, i.e. initial onset, remission and relapse. Moreover, the associations between epitope specificities and clinicopathological features were also analyzed.

In the present study, we constructed six deletion mutants of the single chain of MPO molecule from the propeptide to the light chain and heavy chain. Prepeptide is absent on mature MPO molecule, but it is a part of MPO precursor. Both mature MPO and the precursor form could be detected in the plasma [29]. We could not rule out the possibility that the prepeptide might participate in breaking down the immune tolerance, so we constructed the prepeptide as an epitope site. In the present study, 58.4% of sera from patients with MPO-ANCA positive vasculitis recognized one or more linear epitopes on MPO molecule. We speculated that the other patients might recognize conformational structures of MPO only. Among the 64 AAV patients without co-existing anti-GBM antibodies, 9 (14.1%) sera recognized the prepeptide and 11 (17.2%) sera recognized the light chain. These were inconsistent with Suzuki’s study [28], [30], which reported the negative binding to the light chain. However, our results were consistent with the Bruner’s study [31], which demonstrated that the major epitope sites of MPO-ANCA existed on both the prepeptide and the light chain. In Bruner’s study [31], the antigenic sequences identified on light chain included amino acids (aa) 213–222. In a recent study with a large sample size (74 patients with MPA) by Suzuki et al [28], the light chain was recombined in two parts divided by amino acid 214 and 215, which were among the aa 213–222 in Bruner’s study. The epitope sites on light chain might be just missed. In an early study by Suzuki’s group [30], the light chain was recombined as a whole, but only 4 patients were analyzed in the study. In the present study, the light chain was recombined as a whole, and the results suggested that the reactivity to light chain was not rare in Chinese patients with AAV. In addition, the binding to light chain of MPO-ANCA was associated with more severe renal dysfunction and systemic disease activity in AAV patients. Based on the three-dimensional model of MPO, the light chain is largely ‘hidden’ in the groove between the two MPO monomers and is poorly ‘accessible’ to antibody binding [32], [33]. Once the light chain was recognized, it might suggest that the epitope spreading was much more extensive, which may explain the severity in patients with MPO-ANCA reactivity to the light chain. In addition, patients with antibodies to the light chain reacted to higher number of the recombiant fragments than those without, which suggests an intra-molecular epitope spreading might happen.

In the current study, the epitope sites recognized by MPO-ANCA from AAV patients without serum anti-GBM antibodies displayed a more diverse repertoire, while the epitope sites recognized by MPO-ANCA from AAV patients with coexisting serum anti-GBM antibodies were much less diverse and mainly focused on the N-terminus of the heavy chain. The result indicated that the epitope specificities of MPO-ANCA were different between these two disease phenotypes, i.e. AAV patients with and without anti-GBM antibodies. It was also found in the current study that the recognition frequency to H1 fragment tends to be higher in AAV patients with anti-GBM antibodies than those without anti-GBM antibodies. In addition, the similarity of amino acid sequences 107–112 (GRALEP) of α3(IV)NC1 and amino acid sequences 373–378 (GRALLP) of MPO in H1 fragment raised the question that the H1 fragment might play a role in the development of the two antibodies (MPO-ANCA and anti-GBM antibodies), which still needs further investigation.

Whether the same epitopes are targeted during initial onset and relapse of AAV is an important issue and is not fully clear yet. In the present study, we tested sequential serum samples in 10 patients with AAV, at different stages of the disease, i.e., initial onset, remission and relapse. To the best of our knowledge, this is the first study to map the possible changing or epitope spreading of MPO-ANCA in AAV patients during the relapse of the disease. It was found that in the sera from relapse which recognized linear fragments, the reactivity to linear fragments was similar to that of initial onset. This may suggest a role of “immunological memory” for inducing relapse. In addition, although there was no fixed antibody-binding changing pattern in the three different stages of AAV, the number of recognized epitope sites tends to decrease while remission was achieved. Interestingly, the bindings to H2 fragment in active stage in 5 of the 10 patients all turned negative in remission. The association between binding to H2 fragment and disease activity raised the question that disease-inducing or risk epitope might exist within H2 fragment, which still needs further investigation.

In the present study, about 41.6% of the patients could not recognize the recombined linear peptides. We speculate that the epitopes recognized by these sera might be conformational only. However, those epitopes were not able to be detected with the method employed in this study.

In conclusion, this study provided evidence that MPO-ANCA could recognize linear epitopes throughout the corresponding antigen molecule MPO. The epitope specificities of MPO-ANCA were associated with disease activity and clinical and pathological manifestations in patients with ANCA–associated vasculitis.
Acknowledgments
We are very grateful to Xiao-Yu Jia for her assistance in collecting blood samples and clinic data. We also thank Miao Wang for providing recombinant human α3(V)NC1.

References
1. Falk RJ, Jennette JC (1997) ANCA small-vessel vasculitis. J Am Soc Nephrol 8: 314–322.
2. Chen M, Yu F, Zhang Y, Zhao MH (2005) Clinical and pathological characteristics of Chinese patients with antineutrophil cytoplasmic autoantibody associated systemic vasculitides: a study of 420 patients from a single centre. Postgrad Med J 81: 723–727.
3. Chen M, Yu F, Zhang Y, Zhao MH (2008) Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients. Medicine (Baltimore) 87: 203–209.
4. Chen M, Cui Z, Zhao MH (2010) ANCA-associated vasculitis and anti-GBM disease: the experience in China. Nephrol Dial Transplant 25: 2062–2065.
5. Chen M, Yu F, Zhang Y, Zhou WZ, Zhao MH, et al. (2005) Characteristics of Chinese patients with Wegener’s granulomatosis with anti-myeloperoxidase autoantibodies. Kidney Int 68: 2225–2229.
6. Chen M, Yu F, Wang SX, Zhou WZ, Zhang Y, et al. (2007) Renal histology in Chinese patients with anti-myeloperoxidase autoantibody-positive Wegener’s granulomatosis. Nephrol Dial Transplant 22: 139–145.
7. Hellmack T, Niles JL, Collini AB, McCluskey RT, Brummark C (1997) Comparison of anti-GBM antibodies in sera with or without ANCA. J Am Soc Nephrol 8: 376–385.
8. Short AK, Earnaul VL, Lockwood CM (1995) Anti-neutrophil cytoplasm antibodies and anti-glomerular basement membrane antibodies: two coexisting distinct autoactivities detectable in patients with rapidly progressive glomerulonephritis. Am J Kidney Dis 26: 439–445.
9. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, et al. (2002) Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110: 953–963.
10. Bansal PJ, Tobin MC (2004) Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 93: 398–401.
11. Falk RJ, Terrell RS, Charles LA, Jennette JC (1990) Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 87: 4115–4119.
12. Holland M, Hewins P, Goodall M, Adu D, Jefferis R, et al. (2004) Anti-myeloperoxidase antibodies: identification of candidate human immunodominant epitopes of MPO-ANCA using recombinant hexamer histidine-tagged MPO for epitope analysis of myeloperoxidase (MPO)-specific antineutrophil cytoplasmic autoantibodies (ANCA). Clin Exp Immunol 138: 183–192.
13. Kokolina E, Neil LH, Nishaam P, Gefriand C, Granfeldt JP, et al. (1994) Isotype and affinity of anti-myeloperoxidase autoantibodies in systemic vasculitis. Kidney Int 46: 177–181.
14. Ye H, Zhao MH, Gao Y, Guo XH, Wang HY (2004) Anti-myeloperoxidase antibodies in sera from patients with propylthiouracil-induced vasculitis might recognize restricted epitopes on myeloperoxidase molecule. Clin Exp Immunol 138: 179–182.
15. Arimura Y, Mimoshima S, Kamiya Y, Tanaka U, Nakabayashi K, et al. (1993) Serum myeloperoxidase and serum cytokines in anti-myeloperoxidase antibody-associated glomerulonephritis. Clin Nephrol 40: 236–241.
16. Pankhurst T, Nash G, Williams J, Colman R, Hussain A, et al. (2011) Immunoglobulin subclass determines ability of immunoglobulin IgG to capture and activate neutrophils presented as normal human IgG or disease-associated anti-neutrophil cytoplasm antibody (ANCA)-IgG. Clin Exp Immunol 164: 218–226.
17. Birck R, Schmitt WH, Karlisch IA, Van der Woude FJ (2006) Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitic systemic review. Am J Kidney Dis 47: 15–23.
18. Liu W, Chen M, Zhao MH (2009) Follow-up of avidity and titer of anti-myeloperoxidase antibodies in sera from patients with primary ANCA-associated vasculitis. Autoimmunity 42: 198–202.
19. Liu LJ, Chen M, Yu F, Zhao MH, Wang HY (2008) IgG subclass distribution, affinity of anti-myeloperoxidase antibodies in sera from patients with Wegener’s granulomatosis and microscopic polyangiitis. Nephrology (Carlton) 13: 629–635.
20. Jennette JC, Falk RJ, Andrusky K, Bacon PA, Chung J, et al. (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37: 187–192.
21. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, et al. (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 33: 1101–1107.
22. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, et al. (2007) EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66: 605–617.
23. Zhao MH, Lockwood CM (1996) A comprehensive method to purify three major ANCA antigens: proteasine 3, myeloperoxidase and bacterial/permeability-increasing protein from human neutrophil granule acid extracts. Clin Immunol Methods 197: 121–130.
24. Cui Z, Zhao MH, Xin G, Wang HY (2005) Characteristics and prognosis of Chinese patients with antiglomerular basement membrane disease. Nephron Pract 99: c49–55.
25. Locke IC, Leck B, Canbridge G (1999) A comparison of the characteristics of circulating anti-myeloperoxidase autoantibodies in vasculitis with those in non-vasculitic conditions. Clin Exp Immunol 115: 369–376.
26. Erdbrugger U, Hellmark T, Bunch DO, Alkorta DA, Jennette JC, et al. (2006) Mapping of myeloperoxidase epitopes recognized by MPO-ANCA using human-mouse MPO chimer. Kidney Int 69: 1799–1805.
27. Fujieda M, Suzuki K, Sato H, Hattori M, Wada N, et al. (2005) Epitope analysis of myeloperoxidase-specific antineutrophil cytoplasmic autoantibodies (MPO-ANCA) in childhood onset Graves’ disease treated with propylthiouracil. Clin Nephrol 63: 437–445.
28. Suzuki K, Kobayashi S, Yamazaki K, Gondo M, Tomizawa K, et al. (2007) Analysis of risk epitopes of antineutrophil antibody MPO-ANCA in vasculitis in Japanese population. Microbiol Immunol 51: 1215–1220.
29. Hansson M, Olsson I, Nauseef WM (2006) Biosynthesis, processing, and sorting of human myeloperoxidase. Arch Biochem Biophys 450: 214–225.
30. Tomizawa K, Mine E, Fujii A, Ohashi YY, Yamagoe S, et al. (1998) A panel set for epitope analysis of myeloperoxidase (MPO)-specific antineutrophil cytoplasmic antibody MPO-ANCA using recombinant hexamer histidine-tagged MPO deletion mutants. J Clin Immunol 18: 142–152.
31. Brunner BF, Vista ES, Wynn DM, James JA (2011) Epitope specificity of myeloperoxidase antibodies: identification of candidate human immunodominant epitopes. Clin Exp Immunol 164: 330–336.
32. Zeng J, Fenna RE, (1992) X-ray crystal structure of canine myeloperoxidase at 3.4 A resolution. J Mol Biol 220: 185–207.
33. Chen J, Anderson JB, DeWeese-Scott C, Fedorova ND, Greer LY, et al. (2003) MMDB: Entrez’s 3D-structure database. Nucleic Acids Res 31: 474–477.